HSP90AB1 and breast carcinoma: In fact, tumor growth and angiogenesis are reduced when HSP90 is inhibited by KU-32 interaction with the C-terminal domain of HSP90 in trastuzumab-resistant HER2-positive breast cancer cells [56].